Resumo

GONZALEZ CARDENAS, Víctor Hugo  e  MUNAR GONZALEZ, Freddy Danilo. Sugammadex in the neonatal patient. Rev. colomb. anestesiol. [online]. 2013, vol.41, n.2, pp.171-174. ISSN 0120-3347.

Introduction: The inclusion of drugs that effectively reverse the neuromuscular junction blockade enhances the profile of drugs used for relaxation of the neuromuscular junction; better yet if these agents are free from any clinically important adverse effects and amenable to use in neonates. Objectives: This article describes a case of two pediatric patients who received Sugammadex to reverse neuromuscular relaxation. Methodology: Retrospective, descriptive, observational study designed as a case report. Results: This is a description of a Sugammadex successful reversal of Rocuronium-induced neuromuscular blockade in two neonates with no adverse events. Discussion: The literature on the use of Sugammadex in newborn patients is scarce and controversial which does not contribute to a broad prescription of the drug in neonatology settings due to the shortage of studies attesting to its effectiveness and absence of adverse effects. There are no recommended doses per age group and a list of expected adverse effects to contraindícate its administration. However, the idea is to have available drugs that reverse the relaxation resulting from the use of neuromuscular blockers at any age, including neonates. Conclusions: Following the administration of a dose of Sugammadex the reversal of neuromuscular blockade in neonate patients is described with effective functional recovery of the neuromuscular junction. Further experimental controlled trials are needed to recommend the use of Sugammadex in newborn babies.

Palavras-chave : Infant; Newborn Neuromuscular blocking agents General; Anesthesia Neostigmine.

        · resumo em Espanhol     · texto em Espanhol | Inglês     · Inglês ( pdf ) | Espanhol ( pdf )